NCT06231121Completed
Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab
Short-term Results With Faricimab After Multiple Sequential Treatment Switches Due to Resistance With Both Aflibercept and Ranibizumab in Neovascular Age-related Macular Degeneration
Source: ClinicalTrials.gov · Last updated 30 Jan 2024
Brief summary (registry, in English)
The goal of this retrospective single-center chart review is to establish the response rate, efficacy and safety of a single dose of intravitreal faricimab injection in real-world patients with aflibercept- and ranibizumab-resistant neovascular age-related macular degeneration.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 13 (actual)
- First submitted
- 21 Jan 2024
- Start date
- 1 Dec 2023
- Primary completion date
- 15 Jan 2024
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
- Diseases
- Macular degeneration
- NCT number
- NCT06231121
What you commit to
- Study type: Observational
- Participants enrolled: 13
- From 1 Dec 2023 to the primary completion date, 15 Jan 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Intraocular surgery in the study eye 3 months before or within 1 month after the treatment switch
Other illness
- Neovascular conditions other than AMD (e.g., choroidal neovascularisation due to other causes) or co-existence of other retinal disease in the study eye
Other
- Significant optical media opacities that would result in poor imaging quality on OCT scans in the study eye
Who the study is looking for
- Presence of neovascular age-related macular degeneration (AMD) in the study eye
- Previous treatment with minimum 6 consecutive, monthly aflibercept (Eylea®) injections in the study eye without optimal treatment response, defined as persisting intraretinal fluid or subretinal fluid or both on optical coherence tomography scans
- Subsequently, a sequential switch to ranibizumab (Lucentis®), with minimum 1 injection, also without optimal response
- Finally, a sequential treatment switch from ranibizumab to faricimab.
Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Miklos Schneider Coordinator of this site? Confirm its status | Glostrup Municipality | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.